Abstract |
A 65-year-old male smoker with severe COPD was diagnosed with limited-stage small-cell lung cancer. After receiving cisplatin/ irinotecan, serum progastrin-releasing peptide ( ProGRP) levels decreased to within the reference values and the lesions were markedly reduced in size. A whole-body 18F-fluorodeoxyglucose PET (FDG-PET) scan confirmed complete remission. During follow up, serum ProGRP levels increased, and a whole-body FDG-PET scan detected recurrence at the hilar lymph node that had been negative on CT. Complete remission was again achieved with second-line chemotherapy ( cisplatin/ etoposide) and local irradiation to the hilar lymph node. Monitoring serum ProGRP levels, followed by whole-body FDG-PET when indicated, may improve the clinical management of patients with small-cell lung cancer after initial complete remission.
|
Authors | Hiroyuki Yamaguchi, Hiroshi Soda, Takeshi Kitazaki, Hirofumi Nakano, Satoru Fujino, Yoichi Nakamura, Shigeru Kohno |
Journal | Respirology (Carlton, Vic.)
(Respirology)
Vol. 12
Issue 1
Pg. 137-9
(Jan 2007)
ISSN: 1323-7799 [Print] Australia |
PMID | 17207039
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- Peptide Fragments
- Peptides
- Recombinant Proteins
- pro-gastrin-releasing peptide (31-98)
|
Topics |
- Aged
- Biomarkers, Tumor
(blood)
- Carcinoma, Small Cell
(blood, diagnostic imaging, pathology)
- Disease Progression
- Fatal Outcome
- Humans
- Lung Neoplasms
(blood, diagnostic imaging, pathology)
- Male
- Neoplasm Recurrence, Local
(blood, diagnostic imaging, pathology)
- Peptide Fragments
(blood)
- Peptides
(blood)
- Positron-Emission Tomography
(methods)
- Recombinant Proteins
(blood)
|